Sera Prognostics 2025 Q2 Earnings Sustained Losses Despite Narrowed Net Loss

Sera Prognostics reported its fiscal 2025 Q2 earnings on Aug 06, 2025. The company narrowly reduced its per-share loss to $0.16 from $0.25 a year earlier, and net losses improved to $8.05 million from $8.30 million, a 3.1% reduction. However, these results still reflect continued financial pressure, with the company reporting losses for the sixth consecutive year during the quarter.

Revenue
Sera Prognostics’ total revenue dropped by 29.2% to $17,000 in 2025 Q2, compared to $24,000 in the same period the previous year. This decline signals ongoing challenges in driving commercial traction despite recent leadership additions and engagement with Medicaid programs.

Earnings/Net Income
The company narrowed its net loss to $-8.05 million, a 3.1% improvement compared to the prior year, and reduced its loss per share by 36.0% to $-0.16. Despite these modest improvements, Sera Prognostics has reported a net loss in each of the past six fiscal quarters, underscoring persistent financial strain and the challenges of scaling its operations ahead of revenue growth.

Price Action
The stock price of Sera Prognostics surged 13.17% on the latest trading day but slipped 4.18% during the most recent full trading week. It has rebounded 13.64% month-to-date, reflecting mixed investor sentiment.

Post-Earnings Price Action Review
A strategy of purchasing Sera Prognostics shares 30 days following quarterly earnings releases has underperformed significantly over the past three years. This strategy yielded a CAGR of -0.17% and an excess return of -49.08%, far below the benchmark return of 48.58%. The approach also exhibited a maximum drawdown of 0.00% and a Sharpe ratio of 0.00%, reinforcing its high-risk, low-reward characteristics.

CEO Commentary
Zhenya Lindgardt, President and CEO, emphasized the company's ongoing commercial progress, including engagement with Medicaid programs and the anticipation of full PRIME study results. She highlighted the potential of the PreTRM test to improve pregnancy outcomes and reduce healthcare costs, while also emphasizing prudent capital management ahead of anticipated revenue expansion.

Guidance
Sera Prognostics expects to publish full PRIME study results in 2025, along with data on health economic benefits, sub-population analysis, and Medicaid cost-saving impacts. The company anticipates continued investment in commercialization and market access as it moves toward revenue growth and expects its current cash balance of $108.5 million to fund operations through key milestones into 2028.

Additional News
Sera Prognostics has strengthened its leadership team to support its commercial strategy and investor relations efforts. In May, the company appointed Lee Anderson as Chief Commercial Officer, bringing over 30 years of experience in healthcare sales and marketing. In July, Chuck Hyde was named Head of Market Access, bringing extensive experience in oncology diagnostics and reimbursement, and Jennifer Zibuda joined as Head of Investor Relations. These appointments are intended to bolster the company’s commercial foundation and investor outreach.